Human Hyaluronidase-1(HYAL1) ELISA kit

Instructions
Code CSB-EL010918HU
Size 96T,5×96T,10×96T
See More Details 24T ELISA kits trial application
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Target Name hyaluronoglucosaminidase 1
Alternative Names HYAL 1 ELISA Kit; Hyal-1 ELISA Kit; HYAL1 ELISA Kit; HYAL1_HUMAN ELISA Kit; Hyaluronidase 1 ELISA Kit; Hyaluronidase-1 ELISA Kit; Hyaluronoglucosaminidase 1 ELISA Kit; Hyaluronoglucosaminidase-1 ELISA Kit; Hyaluronoglucosaminidase1 ELISA Kit; LUCA 1 ELISA Kit; LUCA-1 ELISA Kit; LUCA1 ELISA Kit; Lung carcinoma protein 1 ELISA Kit; MGC45987 ELISA Kit; NAT6 ELISA Kit; Plasma hyaluronidase ELISA Kit; Tumor suppressor LUCA 1 ELISA Kit
Abbreviation HYAL1
Uniprot No. Q12794
Species Homo sapiens (Human)
Sample Types serum, plasma, cell culture supernates, tissue homogenates
Detection Range 1.25 ng/mL-80 ng/mL
Sensitivity 0.31 ng/mL
Assay Time 1-5h
Sample Volume 50-100ul
Detection Wavelength 450 nm
Research Area Signal Transduction
Assay Principle quantitative
Measurement Sandwich
Precision
Intra-assay Precision (Precision within an assay): CV%<8%
Three samples of known concentration were tested twenty times on one plate to assess.
Inter-assay Precision (Precision between assays): CV%<10%
Three samples of known concentration were tested in twenty assays to assess.
Linearity
To assess the linearity of the assay, samples were spiked with high concentrations of human HYAL1 in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
 SampleSerum(n=4)
1:1Average %94
Range %90-98
1:2Average %97
Range %92-104
1:4Average %94
Range %90-99
1:8Average %86
Range %82-95
Recovery
The recovery of human HYAL1 spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
Sample TypeAverage % RecoveryRange
Serum (n=5) 8982-95
EDTA plasma (n=4)9189-94
Typical Data
These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
ng/mlOD1OD2AverageCorrected
802.498 2.456 2.477 2.367
401.467 1.540 1.504 1.394
200.803 0.870 0.837 0.727
100.476 0.473 0.475 0.365
50.349 0.358 0.354 0.244
2.50.251 0.253 0.252 0.142
1.250.152 0.160 0.156 0.046
00.111 0.109 0.110  
Troubleshooting
and FAQs
ELISA kit FAQs
Storage Store at 2-8°C. Please refer to protocol.
Lead Time 7-14 working days

Target Data

Function May have a role in promoting tumor progression. May block the TGFB1-enhanced cell growth.
Gene References into Functions
  1. Data revealed a significant inverse correlation between ERalpha and HYAL1 gene expression in human breast tumors. HYAL1 was found repressed by estrogen through ERalpha binding to a consensus response element (ERE) located in the proximal promoter of HYAL1 and flanked by an Sp1 binding site, required to achieve optimal estrogen repression. PMID: 27764788
  2. Ureaplasma urealyticum infection may affect the activity of hyaluronidase on spermatozoa PMID: 28012250
  3. our results suggest that the enzyme HYAL1 plays a role in tumor dissemination and brain-specific colonization, rather than in subsequent metastatic out-growth. PMID: 28168629
  4. HAS2 and HAS3 were the only hyaluronan synthases detected, the expression of which was almost similar in NPs and NM. PMID: 26661071
  5. Molecular docking simulation explains the less favorable binding energy of substrate towards mutant E268K, thereby providing a structural basis for its reduced catalytic activity. PMID: 27424109
  6. The receiver-operating characteristic curve analyses demonstrated that each one had good sensitivity and specificity for distinguishing BC patients from non-BC ones (HYAL1, miR-210, miR-96, lncRNA-UCA1, 91.5 and ). PMID: 26138586
  7. Study showed that reduced HYAL1 expression was associated with endometrial carcinoma aggressiveness, which further supported the role of hyaluronan degradation in cancer progression. PMID: 25584766
  8. Results demonstrated that HYAL1 was C-mannosylated and suggest the possible role of C-mannosylation for secretion and enzymatic activity of HYAL1. PMID: 24820161
  9. In contrast to the previously described MPS IX patient, our three patients display a phenotype limited to the joints, suggesting that this is the primary manifestation of HYAL1 deficiency. PMID: 21559944
  10. Upregulation of HYAL1 expression in breast cancer promoted tumor cell proliferation, migration, invasion and angiogenesis. PMID: 21829529
  11. This is the first report showing high HYAL-1 levels in epithelial ovarian cancer. PMID: 21695196
  12. HYAL-1 and HAS1 expression predicted BCa metastasis, and HYAL-1 expression also predicted disease-specific survival. PMID: 20960509
  13. HYAL1 overexpression is correlated with the malignant behavior of breast cancer. PMID: 20473947
  14. Hyaluronan synthases (HAS1-3) and hyaluronidases (HYAL1-2) in the accumulation of hyaluronan in endometrioid endometrial carcinoma PMID: 20875124
  15. Overexpression of HYAL1 is associated with colorectal cancer. PMID: 20849597
  16. The protein products HABP2 and HYAL1 were associated with plasma PAI-1 concentration and play key roles in hyaluronan metabolism, providing genetic evidence to link these pathways. PMID: 20558613
  17. rhHyal-1 is endocytosed by the liver. PMID: 20572808
  18. HYAL-1 is a potential prognostic marker for predicting progression to muscle invasion and recurrence in bladder cancer. PMID: 19345473
  19. Data show that a significant in expression levels of HA synthases (HASs) and hyaluronidases (Hyals) was observed in vitro on stimulation of epithelial ovarian carcinoma cells by gonadotropins. PMID: 20072653
  20. Characterization of the murine hyaluronidase gene region reveals complex organization and cotranscription of Hyal1 with downstream genes, Fus2 and Hyal3. PMID: 11929860
  21. Alternative mRNA splicing controls cellular expression of enzymatically active hyaluronidase. PMID: 12084718
  22. Down-regulation of HYAL1 is associated with small cell lung cancer and glioma PMID: 12684632
  23. Increased expression of hyaluronidase is associated with head and neck tumors PMID: 12845686
  24. Hyaluronidase and CD44 hyaluronan receptor are expressed in squamous cell laryngeal carcinoma PMID: 16713680
  25. Gene silencing of HYAL1 inhibited cell proliferation and induced cell cycle arrest in human breast cancer cells. PMID: 16831275
  26. HYAL1-v1 transfectants grew 3- to 4-fold slower due to cell cycle arrest in the G(2)-M phase and increased apoptosis. PMID: 17145867
  27. Purified recombinant Hyal-1 from Drosophila cells was used for the investigation of the inhibitory activity of new ascorbic acid derivatives PMID: 17227790
  28. further support to altered glycosaminoglycan metabolism (hyaluronan and hyaluronidase blood levels)in type 1 diabetes as a potential mechanism involved in accelerated atherogenesis. PMID: 17415544
  29. hyaluronan processing by elevated HYAL1 expression in invasive prostate cancer is a requirement for progression. PMID: 17502371
  30. crystal structure reveals a molecule composed of two closely associated domains: a catalytic domain that adopts a distorted (beta/alpha)8 barrel resembling that of bee venom hyaluronidase, and a novel, EGF-like domain PMID: 17503783
  31. Hyaluronidase activity is modulated by complexing with various polyelectrolytes including hyaluronan PMID: 18083358
  32. The expression of HYAL1 in ductal hyperplastic tissues is a strong predictor of subsequent development of invasive breast cancer PMID: 18281563
  33. Bovine serum albumin competes with human hyalurinodase and thus increases hyaluronidase release resulting in a large increase in the hydrolysis rate. PMID: 18677769
  34. HYAL-1 expression is epigenetically regulated by the binding of different transcription factors to the methylated and unmethylated HYAL-1 promoter PMID: 18718911
  35. Down-regulation of RBSP3/CTDSPL, NPRL2/G21, RASSF1A, ITGA9, HYAL1 and HYAL2 genes in non-small cell lung cancer PMID: 19140316
  36. define key components of Hyal1 active site catalysis, and structural factors critical for stability PMID: 19201751
  37. HYAL1, but not HYAL2, expression is reduced and correlates with the accumulation of hyaluronan in ovarian carcinomas. PMID: 19435493
  38. Data showed that the HYAL1 variant exhibited hyaluronan degradation at elevated pH. PMID: 19478093
  39. Invasive features of ER(-) breast cancer cells can be characterized in vitro by higher secretion of hyaluronidase, higher expression of proteinases MMP-9, cath-D, and the angiogenesis promoting factor VEGF. PMID: 19567141

Show More

Hide All

Involvement in disease Mucopolysaccharidosis 9 (MPS9)
Subcellular Location Secreted, Lysosome
Protein Families Glycosyl hydrolase 56 family
Tissue Specificity Highly expressed in the liver, kidney and heart. Weakly expressed in lung, placenta and skeletal muscle. No expression detected in adult brain. Isoform 1 is expressed only in bladder and prostate cancer cells, G2/G3 bladder tumor tissues and lymph node sp
Database Links

HGNC: 5320

OMIM: 601492

KEGG: hsa:3373

STRING: 9606.ENSP00000266031

UniGene: Hs.75619

Most popular with customers

Newsletters

Get all the latest information on Events, Sales and Offers. Sign up for newsletter today.

© 2007-2020 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1